Pharmaceuticals

Pharmacovigilance And Drug Safety Software Market 2026–2030: Forecast, Innovation, and Competitive Trends

March 24, 2026April 6, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmacovigilance and drug safety software market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Pharmacovigilance And Drug Safety Software Market?

The pharmacovigilance and drug safety software market size has observed rapid expansion in recent years. It is projected to increase from $2.53 billion in 2025 to $2.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.8%. The growth experienced in the past can be attributed to factors such as a rise in adverse drug reaction reporting, the globalization of clinical trials, more stringent drug safety regulations, an increase in pharmaceutical production, and rising requirements for post-marketing surveillance.

The pharmacovigilance and drug safety software market is projected for significant expansion in the coming years, reaching $4.6 billion by 2030, propelled by a compound annual growth rate (CAGR) of 12.6%. This anticipated growth stems from factors such as the broader adoption of ai-driven signal detection, the increasing development of biologics and specialty drugs, heightened regulatory scrutiny, the growing trend of outsourcing pharmacovigilance services, and the demand for real-time safety analytics. Key trends identified for this period encompass the increasing integration of cloud-based pharmacovigilance platforms, a sharpened focus on monitoring real-world evidence, greater automation in reporting adverse events, the expansion of integrated drug safety systems, and an elevated demand for regulatory compliance solutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19140&type=smp

What Drivers Are Supporting Technological Adoption In The Pharmacovigilance And Drug Safety Software Market?

The increasing requirement for personalized medicine is projected to stimulate the expansion of the pharmacovigilance and drug safety software market moving forward. Personalized medicine, also referred to as precision medicine, is a healthcare strategy that customizes treatment plans to align with an individual’s genetic, biological, and lifestyle attributes. The impetus for personalized medicine is escalating due to its ability to yield better patient outcomes, enhance prevention and early detection approaches, and offer improved cost-effectiveness. The pharmacovigilance and drug safety software market facilitates personalized medicine by incorporating pharmacogenetics, real-time data analytics, and post-marketing surveillance to maximize patient safety, oversee individualized treatments, and reinforce risk-management protocols. For instance, in February 2024, information from the Personalized Medicine Coalition (PMC), a US-based non-profit organization, highlighted that the FDA granted approval to 16 novel personalized therapies for individuals with rare diseases in 2023, which is a considerable increase from the 6 approvals in 2022. Hence, the rising demand for personalized medicine is a significant catalyst for the growth of the pharmacovigilance and drug safety software market.

What Segment Types Are Examined In The Pharmacovigilance And Drug Safety Software Market?

The pharmacovigilance and drug safety software market covered in this report is segmented –

1) By Software Type: Adverse Event Reporting Software, Drug Safety Audits Software, Issue Tracking Software, Fully Integrated Software

2) By Delivery Mode: On-premise, Cloud-based

3) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Business Process Outsourcing Firms, Other End Users

Subsegments:

1) By Adverse Event Reporting Software: Spontaneous Reporting Systems, EHR Integration Solutions, Mobile Reporting Applications

2) By Drug Safety Audits Software: Audit Management Solutions, Compliance Tracking Tools, Reporting And Analytics Modules

3) By Issue Tracking Software: Incident Reporting Systems, Workflow Management Tools, Collaboration Platforms

4) By Fully Integrated Software: Pharmacovigilance Platforms, Regulatory Compliance Systems, Data Analytics And Visualization Tools

Which Trends Are Influencing The Performance And Direction Of The Pharmacovigilance And Drug Safety Software Market?

Prominent companies within the pharmacovigilance and drug safety software market are directing their attention towards developing novel technologies, including cloud-based data lake platforms, with the goal of strengthening adverse event monitoring, enhancing regulatory compliance, and improving overall patient safety throughout clinical trials and post-market surveillance. A cloud-based data lake platform signifies a scalable, centralized system equipped to store and analyze significant volumes of structured and unstructured safety data instantaneously, thereby enabling sophisticated analytics, AI/ML modeling, and streamlined case processing within pharmacovigilance workflows. For instance, in December 2023, Thermo Fisher Scientific Inc., a US-based biotechnology company, unveiled CorEvidence, its proprietary cloud-based data lake platform specifically engineered to optimize pharmacovigilance processes by refining safety data management and improving case processing efficiency, particularly in its support for post-authorization safety studies within clinical research registries.

Who Are The Top-Performing Companies In The Pharmacovigilance And Drug Safety Software Market In Recent Years?

Major companies operating in the pharmacovigilance and drug safety software market are IQVIA, Oracle Corporation, ArisGlobal, RXLogix, Anju Software Inc., EXTEDO GmbH, Sarjen Systems Pvt Ltd, Ennov Group, AB Cube, Clinevo Technologies, Accenture plc, International Business Machines Corporation, Capgemini SE, Cognizant Technology Solutions, Wipro Limited, Genpact, Indegene Limited, PharmaLex, Deloitte Touche Tohmatsu Limited, Parexel

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-and-drug-safety-software-global-market-report

Which Region Currently Holds The Largest Share Of The Pharmacovigilance And Drug Safety Software Market?

North America was the largest region in the pharmacovigilance and drug safety software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacovigilance and drug safety software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pharmacovigilance And Drug Safety Software Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19140&type=smp

Browse Through More Reports Similar to the Global Pharmacovigilance And Drug Safety Software Market 2026, By The Business Research Company

Pharmacovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Patient Safety And Risk Management Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/patient-safety-and-risk-management-software-global-market-report

Therapeutic Drug Monitoring Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-drug-monitoring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795